The FDA could soon approve the first bispecific antibody for a non-oncology indication, but clinical applications that make full use of the biological opportunity afforded by the nascent modality remain rare.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
13 October 2017
The spelling of John Haurum's last name was incorrect. The error has been corrected in the html and pdf versions online.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Mullard, A. Bispecific antibody pipeline moves beyond oncology. Nat Rev Drug Discov 16, 667–668 (2017). https://doi.org/10.1038/nrd.2017.187
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2017.187
This article is cited by
-
Antibody–drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry
Archives of Pharmacal Research (2023)
-
Bispecific Antibodies for Autoimmune and Inflammatory Diseases: Clinical Progress to Date
BioDrugs (2020)
-
Engineering Antibodies
Journal of the Indian Institute of Science (2018)
-
Erratum: Bispecific antibody pipeline moves beyond oncology
Nature Reviews Drug Discovery (2017)
